Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026)

Capricor Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 2820.64% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $250.3 million (up 66.29% YoY), while the FY2025 annual figure was $248.9 million, up 62.92% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $1.5 million, down from $248.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $248.8 million in Q4 2025, with the low at $3895.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $1.9 million (2022), against an average of $25.5 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 58699.59% in 2024, then sank 99.99% in 2025.
• Capricor Therapeutics' Cash from Financing Activities stood at $2.9 million in 2022, then soared by 685.45% to $23.2 million in 2023, then surged by 250.01% to $81.1 million in 2024, then surged by 206.85% to $248.8 million in 2025, then sank by 99.41% to $1.5 million in 2026.
• Business Quant data shows CAPR's Cash from Financing Activities at $1.5 million in Q1 2026, $248.8 million in Q4 2025, and $6950.0 in Q3 2025.